Teva challenged on possible breach of EU antitrust rules

10 October 2022

The European Commission has informed Israel-based generics behemoth Teva Pharmaceutical Industries (NYSE and TASE: TEVA) of its preliminary view that the company has breached EU antitrust rules by engaging in practices intended to delay competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

These consisted in artificially extending patent protection of Copaxone, over which Teva held a basic patent until 2015, and by systematically spreading misleading information about a competing product with a view to hinder its market entry and uptake. Teva’s US traded shares were down nearly 4% at $8.14 mid-morning.

Copaxone was a $4 billion-a-year blockbuster at its peak in 2014, but sales fell to around $1 billion last year and re predicted to be $700 million this year. In Europe alone, the drug posted second-quarter 2022 sales of $72 million, down 28%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK